Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
Atherosclerosis|December 22, 2014
Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS)Motohiro Shimizu, Norihiro Furusyo, Fujiko Mitsumoto, et al.
Magnetic Resonance in Medical Sciences : MRMS : an Official Journal of Japan Society of Magnetic Resonance in Medicine|February 14, 2020
Increased and More Heterogeneous Gadoxetic Acid Uptake of the Liver Parenchyma after Hepatitis C Virus Eradication by Direct Antiviral AgentNobuhiro Fujita, Akihiro Nishie, Yoshiki Asayama, et al.
Antiviral Research|January 28, 2014
Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infectionEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.
World Journal of Gastroenterology|November 12, 2016
Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetryNobuhiro Fujita, Akihiro Nishie, Yoshiki Asayama, et al.
Comparative Hepatology|May 2, 2007
Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patientsMakoto Nakamuta, Kazuhiro Kotoh, Munechika Enjoji, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 19, 2020
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis BEiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 9, 2019
Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort studyEiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 22, 2019
Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysisEiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, et al.
Antiviral Research|November 7, 2016
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosisEiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 5, 2016
Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosisEiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, et al.
Pageof 20